Ecnoglutide
Novel GLP-1R agonist with next-generation therapeutic design. Enhanced receptor binding affinity and prolonged activity for improved glycemic control and weight management outcomes.
Ecnoglutide is a novel long-acting glucagon-like peptide-1 (GLP-1) receptor agonist engineered for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It combines potent GLP-1 receptor activation with an optimized pharmacokinetic profile, offering effective glycemic control, significant weight reduction, and potential cardiovascular benefits with once-weekly dosing convenience.
| Parameter | Specification |
| CAS | 2459531-73-6 |
| Molecular Formula | C₁₉₄H₃₀₄N₄₈O₆₁ |
| Molecular Weight | 4284.76 g/mol |
| Category | GLP-1/Metabolic |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Type 2 diabetes, obesity, next-generation GLP-1 therapy |
| CAS | 2459531-73-6 |
|---|---|
| Applications |
Related products
-
Lixisenatide
CAS: 320367-13-3Applications: postprandial glucose control, Short-acting GLP-1, Type 2 diabetes -
Mazdutide
CAS: 2259884-03-0Applications: metabolic syndrome, Overweight treatment, Type 2 diabetes -
Survodutide
CAS: 2805997-46-8Applications: Liver Fat, NASH, obesity management, Type 2 diabetes -
GLP-1 (7-37)
CAS: 106612-94-6Applications: Diabetes Research, GLP-1 Analog Development, metabolic syndrome